# ASPU earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/ASPU) · [Earnings tab](https://www.lopjlb.com/stock/ASPU?tab=earnings) Updated: 2026-09-23T07:58:57 Quarters analyzed: 8 ## Cross-quarter narrative Across the series of Aspen Group CallCards the company moved from a period of rapid revenue and enrollment expansion in 2021‑2022 to a phase of contraction and restructuring beginning in late 2022. Early calls highlighted 35% Q4‑2021 revenue growth, strong Phoenix demand and aggressive campus roll‑outs under the Aspen 2.0 cost‑management plan. COVID‑driven RN enrollment drops, higher instructional costs and a voluntary suspension of Phoenix pre‑licensure cohorts in Q3‑2022 forced a lowered FY2022 guidance and a $30 M financing to preserve liquidity. Subsequent quarters saw deep cuts to marketing spend, a teach‑out of pre‑licensure programs, and reliance on a $1.5 M surety bond release and an anticipated accounts‑receivable facility. Gross margins improved as marketing fell, while cash‑flow positivity is targeted for FY2024. Regulatory uncertainties persisted around the Arizona Board of Nursing NCLEX pass‑rate requirement and a DEAC accreditation show‑cause. By Q4‑2024 the firm reported four consecutive quarters of positive EBITDA, modest enrollment growth in postgraduate programs, and ongoing liquidity support from DOE HCM2 reimbursements, but marketing‑driven enrollment risk and accreditation outcomes remain open. ## Latest CallCard · Q2 Aspen Group narrowed its net loss, posted a fourth straight quarter of positive EBITDA and enrollment growth despite reduced marketing, while navigating a teach‑out, pending DEAC accreditation decision and reliance on DOE aid. **Guidance:** vague — Management stated they are not providing guidance at this time. **Tone:** mgmt 0.6 · Q&A pressure 0.1 · divergence 0.2 Prepared remarks highlight positive EBITDA, enrollment gains and cash generation, indicating optimism. ### Demand visibility Demand for postgraduate nursing degrees remains strong. Enrollments at both universities rose over the past two quarters despite minimal internet advertising, driven by robust healthcare industry demand for RN advanced degrees. ### Margins / costs Gross margin improved to 63% due to lower marketing and instructional costs. Reduced marketing spend and the teach‑out of the pre‑licensure program lowered instructional costs, raising gross margin from 60% to 63%. ### Capital allocation Marketing spend cut to maintenance levels with plans to increase later in FY24. Marketing expense fell to $348k (≈3% of revenue) and will be raised to a targeted $500k quarterly later in fiscal 2024 to support enrollment growth. ### Milestones - **Pre‑licensure program teach‑out** [on_track]: Teach‑out expected to finish in Arizona this month and in all remaining states by mid‑2024. - **DEAC Show Cause decision** [at_risk]: Decision anticipated within ~60 days; outcome could affect accreditation. - **DOE HCM2 reimbursement (fifth payment)** [on_track]: $3.9 million expected by end of January 2024. - **Surety bond reduction** [on_track]: Bond reduced from $5.5 M to $2.5 M; seeking alternative provider to free additional cash. - **Unrestricted cash projection** [on_track]: Projected unrestricted cash balance to exceed $2 M after bond reduction and DOE payment. ### Fears / risks - **Regulatory**: DEAC show‑cause directive and potential accreditation outcome. - **Financial**: Reliance on DOE HCM2 reimbursements for cash flow. - **Legal**: Class‑action settlement in Arizona requiring $550k payment. - **Liquidity**: Restricted cash tied to surety bond limits unrestricted cash availability. - **Enrollment**: Reduced marketing spend could suppress future enrollment growth. - **Operational**: Teach‑out of pre‑licensure program reduces instructional revenue. ### Key quotes > “We narrowed our net loss year-over-year by an impressive 30%, helped by our financial discipline amid the wind down of the Aspen University pre-licensure program.” > “We achieved our fourth consecutive quarter of positive EBITDA.” > “Enrollments at Aspen University and United States University have been on the rise over the past two quarters, even given our minimal Internet advertising spend.” > “Total revenue was $13.8 million versus $17.1 million or a decrease of 19%.” > “We plan to resume marketing spend late in fiscal year 2024 to a quarterly targeted spend rate of $500,000.” ## Quarter one-liners - **2024 Q2:** Aspen Group narrowed its net loss, posted a fourth straight quarter of positive EBITDA and enrollment growth despite reduced marketing, while navigating a teach‑out, pending DEAC accreditation decision and reliance on DOE aid. - **2023 Q2:** Aspen Group posted improved gross margin and positive adjusted EBITDA in Q2 FY2023 after deep marketing cuts and restructuring, but enrollment fell sharply and the company still awaits an AR financing facility to fund future marketing spend. - **2023 Q1:** Aspen Group posted Q1 FY2023 revenue of $18.9M, down 3% as enrollment fell and instructional costs rose, while a restructuring aims to cut cash burn and target positive operating cash flow in the second half of fiscal 2023. - **2022 Q4:** Aspen Group cut marketing spend to meet cash‑flow needs, posted positive adjusted EBITDA and revenue growth, highlighted strong USU FNP performance and a promising start at the new Atlanta campus, while noting enrollment headwinds, NCLEX pass‑rate concerns and upcoming breakeven timelines. - **2022 Q3:** Aspen Group posted 14% YoY revenue growth in Q3 2022 but COVID‑driven RN enrollment drops and a voluntary suspension of Phoenix pre‑licensure cohorts led to lowered FY2022 revenue guidance, prompting a $30M financing to bridge to cash‑flow positivity in FY2024. - **2022 Q2:** Aspen Group saw slower revenue growth and a COVID‑driven dip in RN enrollments, but new pre‑licensure campuses are gaining traction, margins are pressured by instructional costs, and guidance reflects a modest recovery with solid cash. - **2022 Q1:** Aspen Group posted 28% YoY revenue growth, highlighted strong enrollment momentum in new metros, drew $5M credit for campus expansion, reiterated full‑year guidance and noted temporary COVID‑Delta impacts on RN starts. - **2021 Q4:** Aspen Group posted 35% Q4 revenue growth, unveiled Aspen 2.0 to focus spending on high‑LTV campuses, targets profitability by Q4 FY22 and guides FY22 revenue up 25‑29% while noting mixed performance of new Tier‑2 campuses. ## Theme arcs - **Revenue growth trajectory** (deteriorating): Growth fell from 35% Q4‑2021 to negative in Q1‑2023, later stabilizing modestly by Q4‑2024 - **Enrollment trends** (deteriorating): Initial expansion gave way to sharp declines and a pre‑licensure teach‑out, with enrollment still below prior peaks - **Margin dynamics** (improving): Margins pressured by instructional costs early, then improved as marketing spend was cut - **Capital financing strategy** (new): Introduced $30 M financing, surety bond reductions and pursued AR financing to support liquidity - **Regulatory risk** (stable): Ongoing concerns about Arizona Board of Nursing NCLEX requirements and DEAC accreditation show‑cause - **Marketing spend strategy** (new): Shifted to maintenance‑level spend with planned ramp‑up in FY24 Q4 - **Campus rollout execution** (deteriorating): Several new campuses on track, but Tampa and Phoenix pre‑licensure sites faced delays and at‑risk status - **Liquidity risk management** (improving): Cash‑flow positivity targeted for FY2024, aided by reduced burn and DOE reimbursements ## Guidance path 2021 Q4:maintained → 2022 Q1:maintained → 2022 Q2:maintained → 2022 Q3:lowered → 2022 Q4:vague → 2023 Q1:vague → 2023 Q2:vague → 2024 Q2:vague --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/ASPU`